HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
FPL 55712
inhibitor of SRS-A and LTC4 and LTD4 receptors
Also Known As:
7-((3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxyl))-4-oxo-8-propyl-4H-chromene-2-carboxy late, sodium salt; FPL-55712
Networked:
51
relevant articles (
4
outcomes,
4
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Pyrans: 130
Benzopyrans: 195
Chromones: 159
FPL 55712: 51
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
Benzopyrans: 195
Chromones: 159
FPL 55712: 51
Related Diseases
1.
Anaphylaxis (Anaphylactic Shock)
04/01/1986 - "
FPL 55712 2 X 10(-6) M did not exert any activity on anaphylaxis in either preparations.
"
09/01/1983 - "
On the other hand, NDGA and FPL 55712 inhibited the less pronounced long-lasting coronary flow reduction in the later phase of cardiac anaphylaxis.
"
06/01/1985 - "
Inhibition of the late phase of anaphylaxis (ANA) by FPL 55712 (10(-5) mol/L) eliminated the post-ANA O(Ca++)E-augmented myorelaxation, suggesting a causal role for SRS-A products.
"
04/01/1986 - "
For this purpose, the actions of nordihydroguaieretic acid (NDGA) and of FPL 55712 were tested during anaphylaxis in guinea-pig ileum and trachea in vitro.
"
09/01/1983 - "
On the other hand, FPL 55712 did not influence the amounts of leukotriene C4-like immunoreactivity released in cardiac anaphylaxis.
"
2.
Hypoxia (Hypoxemia)
05/01/1987 - "
In addition, the pressor response to whole-lung hypoxia was not blocked by an FPL-55712 infusion.
"
09/01/1991 - "
Enhancement of this anaphylactic mediator response was associated with an accentuated and prolonged increase of airway pressure (P less than 0.05, compared with sensitized, antigen-challenged but otherwise untreated sheep), a more intense hypoxemia (P less than 0.0001), and leukopenia (P less than 0.001), changes that were largely eliminated by pretreating with the sulfidopeptide leukotriene (SPLT) antagonist FPL 55712, suggesting that the SPLTs were important mediators of these responses.
"
05/01/1984 - "
FPL 55712, a leukotriene end-organ blocker, in a dose which inhibited vasoconstriction caused by exogenous leukotriene C4, inhibited the pressor response to hypoxia but not to angiotensin II. We conclude that leukotriene inhibitors preferentially inhibit hypoxic pulmonary vasoconstriction in isolated perfused adult rat lungs.
"
01/01/1992 - "
The arteries were contracted by hypoxia (PO2 43 +/- 2 Torr) developing a tension of 127 +/- 36 mg over the course of 15 min. This contraction was completely blocked by 10(-6) M L-isoproterenol, 10(-6) M nitroglycerin, partially blocked by 10(-8)-10(-6) M verapamil, unchanged by 10(-6) M phentolamine, 10(-6) M L-propranolol, 10(-6) M diphenhydramine, 10(-6) M guanethidine, 10(-7) M FPL 55712 and enhanced by 10(-6) M BAY K 8644, 10(-3) M procaine, 3 x 10(-6) M quinacrine, 10(-6) M indomethacin or 10(-6) M methylene blue.
"
3.
Leukopenia
06/24/1986 - "
The addition of FPL 55712 and PGI2 to this cocktail of drugs additionally inhibited the thrombocytopenia and leukopenia but not the intrathoracic accumulation of platelets induced by antigen challenge.
"
09/01/1991 - "
Enhancement of this anaphylactic mediator response was associated with an accentuated and prolonged increase of airway pressure (P less than 0.05, compared with sensitized, antigen-challenged but otherwise untreated sheep), a more intense hypoxemia (P less than 0.0001), and leukopenia (P less than 0.001), changes that were largely eliminated by pretreating with the sulfidopeptide leukotriene (SPLT) antagonist FPL 55712, suggesting that the SPLTs were important mediators of these responses.
"
10/01/1986 - "
Bronchoconstriction, but not leukopenia, was inhibited by aspirin, whereas the peptido-leukotriene antagonist compound FPL 55712 and the cyclo-oxygenase lipoxygenase inhibitor indomethacin reduced bronchoconstriction to a limited extent only.
"
4.
Weight Gain
11/01/1990 - "
Posttreatment with 5,8,11,14-eicosatetraynoic acid (ETYA), a nonmetabolized competitive inhibitor of arachidonic acid metabolism, or the leukotriene receptor blockers, FPL 55712 and LY 171883, also dramatically reduced the lung weight gain caused by phosgene.
"
5.
Myocardial Ischemia (Ischemic Heart Diseases)
04/01/1990 - "
This study shows that FPL-55712 does not modulate the thrombolytic potential of t-PA even though it decreases neutrophil activation in response to myocardial ischemia.
"
08/01/1987 - "
Diphenhydramine, 1 mg/kg (n = 6), abolished the histamine-induced coronary spasm FPL-55712, 0.1 mg/kg, with which the LT-induced myocardial ischemia was abolished, did not prevent the histamine-induced coronary artery spasm.(ABSTRACT TRUNCATED AT 250 WORDS)
"
Related Drugs and Biologics
1.
Leukotrienes
2.
SRS-A
3.
Antigens
4.
4,5- Dihydro- 1- (3- (trifluoromethyl)phenyl)- 1H- pyrazol- 3- amine
5.
Leukotriene Receptors (Leukotriene Receptor)
6.
Arachidonic Acid (Vitamin F)
7.
5,8,11,14-Eicosatetraynoic Acid (5,8,11,14 Eicosatetraynoic Acid)
8.
Naloxone (Narcan)
9.
Dexamethasone (Maxidex)
10.
Phosgene
Related Therapies and Procedures
1.
Vagotomy
2.
Intravenous Administration